Skip to search formSkip to main contentSkip to account menu

interleukin-2/lymphokine-activated killer cells

Known as: IL-2/LAK, IL2/LAK 
National Institutes of Health

Related topics

Related topics

8 relations
Adoptive ImmunotherapyAldesleukinImmunologic CytotoxicityInterleukin-2

Broader (1)

Killer Cells

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Radiochemotherapy combined with IL-2/LAK therapy for locally advanced NSCLC with postoperative residual cancer
Objective To evaluate the efficacy of ratiochemotherapy combined with interleukin-2 / lymphokine activated killer( IL-2 / LAK… 
2006
2006
Lymphokine-activated Killer Cells Treated with Recombinant Interleukin 2 and Circulating Cytokines in Patients with Metastatic Cancer
Treatment with recombinant interleukin 2 and lymphokine-activated killer cells (rIL-2/LAK) has produced a clinical antitumor… 
Review
2005
Review
2005
IL-2/LAK-THERAPY PROBLEMS IN CLINIC
N. N. Blokhin Russian Cancer Research Center RAMS, MoscowABSTRACTThe review article on clinical effectiveness of IL-2/LAK-therapy… 
2004
2004
To the editor
Recent reports by West et al., [1] and Rosenberg et al., [2] demonstrate the effectiveness of using human lymphokine activated… 
2000
2000
Effects of IL-2/LAK Cells on Cellular Immuno function in Patients with Nasopharyngeal Carcinoma After Radiotherapy
ObjectiveTo evaluate the effects of IL 2/LAK cells on the cellular immuno function in patients with nasopharyngeal carcinoma(NPC… 
1996
1996
Feasibility of Combined Anticancer with Chemotherapeutic Drugs and IL-2/LAK cells
Kinds of chemotherapeutic drugs often used mere studied by 3H-TdR releaseassays to detect their effects on IL-2/LAK activity. The… 
1994
1994
Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma.
The dose of interleukin 2 (IL-2) which can be administered to cancer patients is limited largely by a capillary leak syndrome… 
1991
1991
Enhanced survival of IFN-alpha augmented IL-2 therapy of pulmonary metastases: efficacy comparable to interleukin-2 and lymphokine activated killer cells.
Recently, we reported enhanced tumor reduction using recombinant interferon-alpha A/D (IFN) combined with interleukin-2 (IL-2… 
1989
1989
Studies confirm value of IL-2/LAK treatment.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)